Orlistat and the risk of acute liver injury: Self controlled case series study in UK Clinical Practice Research Datalink

BMJ (Online)

Volumn 346, Issue 7906, 2013, Pages

  Douglas, Ian J ^a   Langham, Julia ^a   Bhaskaran, Krishnan ^a   Brauer, Ruth ^a   Smeeth, Liam ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; INCIDENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; ANTI-OBESITY AGENTS; CASE-CONTROL STUDIES; CAUSALITY; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LACTONES; MALE; MIDDLE AGED; OBESITY; TIME FACTORS;

EID: 84877624422     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1936     Document Type: Article

References (14)

1. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl 3):S12-23. (Pubitemid 27271984)
2. Food and Drug Administration. Orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review. FDA, 2009. 2012. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm180025.htm.
3. Food and Drug Administration. Drug safety communication: completed safety review of Xenical/Alli (orlistat) and severe liver injury. FDA, 2010. 2012. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm.
4. European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines. 2012. www.ema.europa.eu/docs/en-GB/document- library/Press-release/2012/02/WC500122878.pdf.
5. Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts 2012;5:485-94. doi:10.1159/000341589. Published online 23 Jul. 2012.
6. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Q J Med 1998;91:445-52. (Pubitemid 28286844)
7. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25. (Pubitemid 28227341)
8. Office for National Statistics. Key health statistics from general practice 1998. Office for National Statistics, 2000:149. Series MB6 No. 2.
9. Hospital Episode Statistics. Hospital Episode Statistics Online. 2012. www.hesonline.nhs.uk/.
10. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006;25:1768-97.
11. Whitaker HJ, Hocine M, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009;18:7-26.
12. Pratt NL, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for stroke associated with antipsychotic use in the elderly. Drugs Aging 2010;27:885-93
13. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68.
14. Food and Drug Administration. Questions and answers: Orlistat and severe liver injury. FDA, 2010. 2012. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213040.htm.